Driehaus Capital Management LLC Has $21.74 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Driehaus Capital Management LLC increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 52.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 264,217 shares of the medical instruments supplier’s stock after buying an additional 90,573 shares during the quarter. Driehaus Capital Management LLC owned 1.18% of LeMaitre Vascular worth $21,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co increased its stake in shares of LeMaitre Vascular by 44.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after buying an additional 6,875 shares during the period. Quantbot Technologies LP boosted its holdings in LeMaitre Vascular by 1,001.4% in the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after acquiring an additional 6,669 shares during the last quarter. Ranger Investment Management L.P. boosted its holdings in LeMaitre Vascular by 1.5% in the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after acquiring an additional 13,681 shares during the last quarter. Congress Asset Management Co. MA boosted its holdings in LeMaitre Vascular by 12.0% in the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after acquiring an additional 71,411 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after acquiring an additional 38,303 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LMAT. Lake Street Capital began coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. Barrington Research reiterated an “outperform” rating and issued a $92.00 target price on shares of LeMaitre Vascular in a report on Friday, September 20th. JMP Securities upped their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.40.

Insider Buying and Selling

In related news, Director David B. Roberts sold 3,063 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director David B. Roberts sold 3,063 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold a total of 43,251 shares of company stock worth $3,714,994 in the last ninety days. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $91.71 on Friday. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of 60.74, a PEG ratio of 2.41 and a beta of 0.88. LeMaitre Vascular, Inc. has a 52-week low of $44.27 and a 52-week high of $92.90. The stock’s 50 day moving average price is $87.29 and its two-hundred day moving average price is $78.81.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same period last year, the business earned $0.37 EPS. LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.85 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.